Aprinoia Therapeutics locks in $11.1 mln Series B
Aprinoia Therapeutics Inc, a clinical-stage neuroscience biotech company, focuses on tau, alpha-synuclein, and novel targets for neurodegenerative diseases, has closed $11.1 million in Series B funding. KTB Network and DCI Partners led the round with participation from ShangPharma Investment Group and TaiAn Technologies.
16 January 2018•1 min read
